TN2013000392A1 - Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor - Google Patents
Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitorInfo
- Publication number
- TN2013000392A1 TN2013000392A1 TNP2013000392A TN2013000392A TN2013000392A1 TN 2013000392 A1 TN2013000392 A1 TN 2013000392A1 TN P2013000392 A TNP2013000392 A TN P2013000392A TN 2013000392 A TN2013000392 A TN 2013000392A TN 2013000392 A1 TN2013000392 A1 TN 2013000392A1
- Authority
- TN
- Tunisia
- Prior art keywords
- inhibitor
- combination
- kinase
- pi3k
- phosphatidylinositol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161478572P | 2011-04-25 | 2011-04-25 | |
PCT/US2012/034647 WO2012148846A1 (fr) | 2011-04-25 | 2012-04-23 | Association d'un inhibiteur de phosphatidylinositol-3-kinase (pi3k) et d'un inhibiteur de mtor |
Publications (1)
Publication Number | Publication Date |
---|---|
TN2013000392A1 true TN2013000392A1 (en) | 2015-01-20 |
Family
ID=46018130
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TNP2013000392A TN2013000392A1 (en) | 2011-04-25 | 2013-09-27 | Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor |
Country Status (25)
Country | Link |
---|---|
US (3) | US20140066474A1 (fr) |
EP (1) | EP2701703A1 (fr) |
JP (2) | JP6086902B2 (fr) |
KR (1) | KR101925656B1 (fr) |
CN (1) | CN103491955B (fr) |
AR (1) | AR086481A1 (fr) |
AU (2) | AU2012250010A1 (fr) |
BR (1) | BR112013027486A2 (fr) |
CA (1) | CA2833962A1 (fr) |
CL (1) | CL2013003078A1 (fr) |
CO (1) | CO6801759A2 (fr) |
EA (1) | EA025948B1 (fr) |
EC (1) | ECSP13012994A (fr) |
GT (1) | GT201300263A (fr) |
IL (1) | IL229008A (fr) |
MA (1) | MA35038B1 (fr) |
MX (1) | MX2013012385A (fr) |
NZ (1) | NZ615593A (fr) |
PE (1) | PE20140601A1 (fr) |
SG (1) | SG193919A1 (fr) |
TN (1) | TN2013000392A1 (fr) |
TW (1) | TWI602567B (fr) |
UA (1) | UA110961C2 (fr) |
WO (1) | WO2012148846A1 (fr) |
ZA (1) | ZA201306973B (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013064567A1 (fr) * | 2011-11-02 | 2013-05-10 | Novartis Ag | Dérivés de 2-carboxamide-cycloamino-urée destinés à être utilisés dans le traitement de maladies dépendant du vegf |
WO2014151147A1 (fr) * | 2013-03-15 | 2014-09-25 | Intellikine, Llc | Combinaison d'inhibiteurs de kinase et ses utilisations |
BR112016010716A8 (pt) * | 2013-11-13 | 2020-04-22 | Novartis Ag | dose de reforço imunológico, baixa, de um inibidor de mtor, seu uso, e adjuvante de vacina |
US20170165246A1 (en) * | 2014-02-11 | 2017-06-15 | Novartis Ag | Pharmaceutical combinations comprising a pi3k inhibitor for the treatment of cancer |
WO2015148626A1 (fr) * | 2014-03-26 | 2015-10-01 | Millennium Pharmaceuticals, Inc. | Traitement d'affections fibrotiques |
BR112017004694A2 (pt) * | 2014-10-03 | 2017-12-05 | Novartis Ag | composições farmacêuticas compreendendo alpelisibe |
US20160339030A1 (en) | 2015-05-19 | 2016-11-24 | University Of Maryland, Baltimore | Treatment agents for inhibiting hiv and cancer in hiv infected patients |
GB202010627D0 (en) * | 2020-07-10 | 2020-08-26 | Qbd (Qs-Ip) Ltd | Blocking method |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT98990A (pt) | 1990-09-19 | 1992-08-31 | American Home Prod | Processo para a preparacao de esteres de acidos carboxilicos de rapamicina |
US5120842A (en) | 1991-04-01 | 1992-06-09 | American Home Products Corporation | Silyl ethers of rapamycin |
US5100883A (en) | 1991-04-08 | 1992-03-31 | American Home Products Corporation | Fluorinated esters of rapamycin |
US5118678A (en) | 1991-04-17 | 1992-06-02 | American Home Products Corporation | Carbamates of rapamycin |
US5118677A (en) | 1991-05-20 | 1992-06-02 | American Home Products Corporation | Amide esters of rapamycin |
US5151413A (en) | 1991-11-06 | 1992-09-29 | American Home Products Corporation | Rapamycin acetals as immunosuppressant and antifungal agents |
GB9125660D0 (en) | 1991-12-03 | 1992-01-29 | Smithkline Beecham Plc | Novel compound |
ZA935111B (en) | 1992-07-17 | 1994-02-04 | Smithkline Beecham Corp | Rapamycin derivatives |
ZA935112B (en) | 1992-07-17 | 1994-02-08 | Smithkline Beecham Corp | Rapamycin derivatives |
US5256790A (en) | 1992-08-13 | 1993-10-26 | American Home Products Corporation | 27-hydroxyrapamycin and derivatives thereof |
GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
US5258389A (en) | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
EP0729471A1 (fr) | 1993-11-19 | 1996-09-04 | Abbott Laboratories | Analogues semi-synthetiques de rapamycine (macrolides) utilises comme immunomodulateurs |
ATE191218T1 (de) | 1993-12-17 | 2000-04-15 | Novartis Ag | Rapamycin-derivate als immunosuppressoren |
CA2219659C (fr) | 1995-06-09 | 2008-03-18 | Novartis Ag | Derives de rapamycine |
US6258823B1 (en) | 1996-07-12 | 2001-07-10 | Ariad Pharmaceuticals, Inc. | Materials and method for treating or preventing pathogenic fungal infection |
AU783158B2 (en) | 1999-08-24 | 2005-09-29 | Ariad Pharmaceuticals, Inc. | 28-epirapalogs |
TW200519106A (en) * | 2003-05-02 | 2005-06-16 | Novartis Ag | Organic compounds |
EP1962839A4 (fr) * | 2005-11-14 | 2010-08-25 | Ariad Pharma Inc | Administration d'un inhibiteur de mntor pour le traitement des patients atteints du cancer |
UA104147C2 (uk) * | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
JP2012506898A (ja) * | 2008-10-31 | 2012-03-22 | ノバルティス アーゲー | ホスファチジルイノシトール−3−キナーゼ(PI3K)阻害剤とmTOR阻害剤との併用剤 |
-
2012
- 2012-04-23 US US14/113,316 patent/US20140066474A1/en not_active Abandoned
- 2012-04-23 KR KR1020137027718A patent/KR101925656B1/ko active IP Right Grant
- 2012-04-23 NZ NZ615593A patent/NZ615593A/en not_active IP Right Cessation
- 2012-04-23 EA EA201391565A patent/EA025948B1/ru not_active IP Right Cessation
- 2012-04-23 WO PCT/US2012/034647 patent/WO2012148846A1/fr active Application Filing
- 2012-04-23 EP EP12717568.5A patent/EP2701703A1/fr not_active Withdrawn
- 2012-04-23 AR ARP120101389A patent/AR086481A1/es unknown
- 2012-04-23 BR BR112013027486A patent/BR112013027486A2/pt not_active Application Discontinuation
- 2012-04-23 AU AU2012250010A patent/AU2012250010A1/en not_active Abandoned
- 2012-04-23 CA CA2833962A patent/CA2833962A1/fr not_active Abandoned
- 2012-04-23 PE PE2013002391A patent/PE20140601A1/es not_active Application Discontinuation
- 2012-04-23 CN CN201280020528.4A patent/CN103491955B/zh not_active Expired - Fee Related
- 2012-04-23 MA MA36325A patent/MA35038B1/fr unknown
- 2012-04-23 UA UAA201311138A patent/UA110961C2/uk unknown
- 2012-04-23 SG SG2013070461A patent/SG193919A1/en unknown
- 2012-04-23 JP JP2014508463A patent/JP6086902B2/ja not_active Expired - Fee Related
- 2012-04-23 MX MX2013012385A patent/MX2013012385A/es unknown
- 2012-04-24 TW TW101114591A patent/TWI602567B/zh not_active IP Right Cessation
-
2013
- 2013-09-17 ZA ZA2013/06973A patent/ZA201306973B/en unknown
- 2013-09-27 TN TNP2013000392A patent/TN2013000392A1/fr unknown
- 2013-10-21 IL IL229008A patent/IL229008A/en active IP Right Grant
- 2013-10-24 CO CO13252726A patent/CO6801759A2/es not_active Application Discontinuation
- 2013-10-24 CL CL2013003078A patent/CL2013003078A1/es unknown
- 2013-10-25 GT GT201300263A patent/GT201300263A/es unknown
- 2013-10-25 EC ECSP13012994 patent/ECSP13012994A/es unknown
-
2016
- 2016-04-14 AU AU2016202372A patent/AU2016202372B2/en not_active Ceased
- 2016-10-27 US US15/335,957 patent/US20170095463A1/en not_active Abandoned
- 2016-11-18 JP JP2016224893A patent/JP2017061527A/ja active Pending
-
2017
- 2017-09-26 US US15/715,865 patent/US20180085362A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TN2013000392A1 (en) | Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor | |
PH12018501807A1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of diseas | |
EA201692506A3 (ru) | Ингибиторы репликации вирусов гриппа | |
PH12014502757B1 (en) | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | |
PH12014502739A1 (en) | Macrocyclic inhibitors of flaviviridae viruses | |
NZ724503A (en) | Macrocyclic inhibitors of flaviviridae viruses | |
MX2011011335A (es) | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamifero de rapamicina. | |
AU2012284088A8 (en) | Heterocyclic compounds and uses thereof | |
MX2013006475A (es) | Inhibidores macrociclicos de virus flaviviridae. | |
MX2009008486A (es) | Imidazoquinolinas como inhibidores dobles de cinasa de lipido y mtor. | |
GEP201706624B (en) | Triazolopyrazine as brd4 inhibitors and usage thereof for cancer treatment | |
NZ703066A (en) | Macrocyclic inhibitors of flaviviridae viruses | |
NZ703064A (en) | Inhibitors of hepatitis c virus | |
UA114906C2 (uk) | Гетероциклільні сполуки як інгібітори мек | |
WO2013052699A3 (fr) | Nouveaux inhibiteurs de quinoxaline de la voie pi3k | |
EA201000091A1 (ru) | ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K | |
MY189427A (en) | Pyrazolyl quinoxaline kinase inhibitors | |
MX2015016421A (es) | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades. | |
EA201390198A1 (ru) | Гетероциклическое соединение | |
MX2013012588A (es) | Inhibidores de cinasa. | |
GEP20166474B (en) | Pyrazolospiroketone derivatives for use as acetyl-coa carboxylase inhibitors | |
CL2014000849A1 (es) | Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas. | |
NZ706591A (en) | Oxazolidin-2-one-pyrimidine derivatives | |
EA032271B9 (ru) | Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний | |
MX2016006667A (es) | Derivados de pirrolo-pirrolona y su uso como inhibidores. |